Innate Pharma : 2023 : principaux catalyseurs attendus au S2
>Une visibilité financière jusqu’à mi-2025 - Innate Pharma communique ses chiffres au titre de l’exercice 2022. Les revenus opérationnels progressent à 57.7 M€ (vs 24.7 M€ en 2021) provenant principalement des 1/ encaissements reçus dans le cadre des accords de partenariats avec Astrazeneca et Sanofi (49.6 M€) et 2/ du Crédit Impôt Recherche de l’année 2022 (8 M€). Notons, par ailleurs, la constatation d’une dépréciation de 41 M€ liée à l’arrêt du programme avdor...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.